Covagen has announced that the company has secured CHF42m in a tranched Series B financing with an option to obtain an additional CHF14m that would increase the total amount of the financing round to CHF56m. This financing will mainly ...
OncoMed Pharmaceuticals and Celgene have entered into an agreement to jointly develop and commercialize about six anti-cancer stem cell (CSC) product candidates from OncoMed's biologics pipeline, including demcizumab (OMP-21M18, Anti-DLL4). ...
Tags: clinical studies, Medicine, OncoMed
US-based biopharmaceutical company Immunomedics has announced the issuance of a US patent to its majority-owned subsidiary, IBC Pharmaceuticals, for ‘Novel Strategies for Improved Cancer Vaccines’. The new patent concerns ...
Immunomedics has developed two new classes of bispecific antibodies, DOCK-AND-LOCK (DNL) complexes using its patented platform technology that enables site-specific conjugation of two self-assembling modules. The bispecific antibodies ...